Hypertension liver-yang hyperactivity rat model discrimination method and application thereof

Abstract

The invention provides a hypertension liver-yang hyperactivity rat model discrimination method. According to the discrimination method, discrimination indexes are comprehensive, and special material groups generated in the hypertension liver-yang hyperactivity occurrence and development process are included. The method comprises the steps that a hypertension liver-yang hyperactivity rat model is copied as a disease group, macroscopic and biochemical physical indexes are measured, data is selected and brought into the hypertension liver-yang hyperactivity rat PLS regression model, if the disease group and the model group in a PLS two-dimensional score plot are separated, the built hypertension liver-yang hyperactivity rat model is successful, and if not, the built hypertension liver-yang hyperactivity rat model is not successful.

Description

technical field [0001] The invention belongs to the technical field of medicine, and the invention relates to a rat model discrimination method of hypertensive liver-yang syndrome and its application. The method is used for evaluating the hypertensive rat model of liver-yang hyperactivity. Background technique [0002] Combination of disease and syndrome animal models refers to the combination of modern medical theory and experimental animal science knowledge under the guidance of traditional Chinese medicine theory, respectively or at the same time, using traditional Chinese medicine etiology to replicate syndrome animal models and modern medical etiology to replicate disease animal models to make animals The model can not only reflect the pathological characteristics of the disease, but also systematically and dynamically reflect the syndrome characteristics that appear in this specific stage. Syndrome of hyperactivity of liver-yang in hypertension is a common syndrome typ...

AI Technical Summary

Problems solved by technology

The simple superposition of several physical and chemical indicators is used to explain the syndrome of hyperactivity of liver yang. This inconsistency in the corresponding levels makes it difficult to describe the syndrome objectively.

Secondly, when refuting the animal model of hyperactivity of liver-yang syndrome in hypertension, one should carefully select a prescription that is effective and has a clear mechanism, so as to use this as a basis to observe the effect of the prescription after the model, and judge whether the established animal model has The nature of hyperactivity of liver-yang syndrome in hypertension, and the anti-symbol prescriptions currently used in clinical practice are mostly clinical empirical prescriptions, and their pharmacological mechanisms have not been studied in depth

In addition, when looking back at the previous method of "testing syndromes with prescriptions", usually only the normal group, the hypertensive liver-yang hyperactivity syndrome group (model group) and the syndrome-testing prescription group were set up, and there was often a lack of a control group. The efficacy obtained by the prescription cannot be simply judged as the attribute of the syndrome

Images